Szántó Kata Judit, Balázs Tamás, Schrempf Dóra Mihonné, Farkas Klaudia, Molnár Tamás
Department of Medicine, University of Szeged, Szeged, Hungary.
Healthware Consulting Ltd., Budapest, Hungary.
Therap Adv Gastroenterol. 2021 Feb 27;14:1756284820986670. doi: 10.1177/1756284820986670. eCollection 2021.
There is a lack of data about demographic and treatment characteristics of adolescent patients with inflammatory bowel disease (IBD). The aim of this retrospective, epidemiological study was to evaluate characteristics and therapeutic features of Hungarian adolescents with IBD.
We analysed the social security databases of the National Health Insurance Fund. Adolescent patients with IBD for whom data from 2009 to 2016 were observable in the database were enrolled. Patients aged 14 to 17 years and 18 to 21 years were defined as middle and late adolescent patients.
The incidences of IBD were 20.12 per 100,000 middle adolescent patients and 29.72 per 100,000 late adolescent patients. Admission to gastroenterology department was higher in both groups compared with admissions to surgery department. Mesalazine was used by a high proportion of Crohn's disease and ulcerative colitis patients. Rates of corticosteroid use were similar in both groups, with a tendency to decrease over time. The need for biologic agents was higher in the middle adolescent patients. The proportion of patients in the middle adolescent group who received anti-TNF therapy showed an increasing tendency.
Our data suggest differences in the treatment strategies of gastroenterologists for these age groups. The greater need of anti-TNF therapy among the middle adolescent group indicates that adolescent patients before the transition to adult care may have a more severe disease phenotype. We expect that a strategy of early, effective treatment will significantly ameliorate the subsequent disease course, which is manifested in adult care.
关于炎症性肠病(IBD)青少年患者的人口统计学和治疗特征的数据匮乏。这项回顾性流行病学研究的目的是评估匈牙利IBD青少年患者的特征和治疗特点。
我们分析了国家健康保险基金的社会保障数据库。纳入数据库中2009年至2016年数据可查的IBD青少年患者。年龄在14至17岁和18至21岁的患者分别被定义为青少年中期和晚期患者。
青少年中期患者IBD发病率为每10万人20.12例,青少年晚期患者为每10万人29.72例。两组患者入住胃肠病科的比例均高于入住外科的比例。高比例的克罗恩病和溃疡性结肠炎患者使用美沙拉嗪。两组患者使用皮质类固醇的比例相似,且有随时间下降的趋势。青少年中期患者对生物制剂的需求更高。青少年中期组接受抗TNF治疗的患者比例呈上升趋势。
我们的数据表明胃肠病学家针对这些年龄组的治疗策略存在差异。青少年中期组对抗TNF治疗的需求更大,这表明向成人护理过渡前的青少年患者可能具有更严重的疾病表型。我们期望早期有效治疗策略将显著改善后续疾病进程,这在成人护理中有所体现。